# Oxford BioMedica plc -5.9% potential downside indicated by Deutsche

- Link: https://www.directorstalkinterviews.com/oxford-biomedica-plc-5.9-potential-downside-indicated-by-deutsche/4121176211
- Published: 2024-11-04T14:21:36+00:00
- Author: Charlotte Edwards

**Oxford BioMedica plc** with ticker (LON:OXB) now has a potential downside of -
5.9% according to Deutsche.
OXB.LDeutsche set a target price of 380 GBX for the 
company, which when compared to the Oxford BioMedica plc share price of 404 GBX 
at opening today (04/11/2024) indicates a potential downside of -5.9%. Trading has
ranged between 164 (52 week low) and 450 (52 week high) with an average of 195,441
shares exchanging hands daily. The market capitalisation at the time of writing 
is £434,925,241.Oxford Biomedica PLC is a contract development and manufacturing
organization (CDMO) in cell and gene therapy. It provides viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus
and other viral vector types. It offers several technologies for viral vector manufacturing,
including a 4th generation lentiviral vector system (the Tetravecta system), dual
plasmid system for AAV production, suspension and perfusion process using process
enhancers and stable producer and packaging cell lines. It has bioprocessing and
manufacturing facilities across Oxfordshire, United Kingdom, Lyon and Strasbourg,
France and near Boston, MA, United Sates. Its Platform segment is involved in bioprocessing
and process development activities undertaken for third parties. Its Viral Vector
includes LentiVector platform, inAAVate platform, and Other Viral Vectors. Its LentiVector
platform technology is an advanced lentiviral vector-based gene delivery system.

Share on: